PNPLA3 and metabolic syndrome: Consistent with this view, our data show that carriers of the G allele in PNPLA3 not only had a better metabolic profile (i.e., lower glucose and glycated hemoglobin) but also lower blood pressure, pulse pressure, cSBP, aortic stiffness, IMT, and cardiovascular risk, as compared to patients with metabolic syndrome-related steatotic liver disease.